Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

BioPharma Drive: Drug Pricing

MARCH 18, 2024

The funding could extend the cash-strapped gene therapy maker’s financial runway to 2026, but only if the company successfully hits certain milestones.

Therapies 68

Therapies 68

Drug Hunter

APRIL 24, 2023

A landmark part of the act is the requirement of Medicare to negotiate the prices for the 15 drugs with highest Medicare spend without generic and/or biosimilar substitutions across Part B (hospital drugs) and D (at-home drugs), with negotiated price implementation starting in 2026.

Small Molecule 130

Small Molecule Biosimilars Drugs Vaccine 130

Drug Discovery World

NOVEMBER 14, 2022

billion by 2026, at a compound annual growth rate (CAGR) of 28.4% during the forecast period of 2021-2026. BCC Research reports that the global market for synthetic biology is estimated to increase from $9.5 billion in 2021 to $33.2 This highlights its potential and underlines its appeal to investors. .

DNA 130

DNA Drugs Engineering Production 130

Drug Discovery World

AUGUST 21, 2023

In a 2021 study in Texas , US, exenatide in combination with the nicotine replacement therapy was proved to improve smoking abstinence, reduce craving and withdrawal symptoms, and decrease weight gain among abstainers. However, these trials won’t be complete until 2026 at the earliest. appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Trials Treatment Licensing 130

Drug Discovery World

OCTOBER 13, 2022

mRNA technology is proving to be the rising star of nucleic acid therapies and a practical, versatile route offering developers opportunities to innovate therapies beyond vaccines. In particular, mRNA technology is proving to be the rising star of nucleic acid therapies processes. billion by 2026 9. billion by 2026 9.

Vaccine 130

Vaccine Therapies Drugs RNA 130

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

Drug Discovery World

FEBRUARY 22, 2024

There is now hope that new treatments will arise to overcome the limitations of existing therapies and relieve the millions of patients suffering worldwide 4 ”. The report also highlights that the global neuroscience market (GNM) “was worth $612 billion in 2022 and could grow to $721 billion by 2026.

Drugs 147

Drugs Clinical Trials Disease Therapies 147

Drug Discovery World

JULY 1, 2024

billion DKK ($11.97 billion) in 2023, 51% higher than 2022, marking the company’s largest annual net profit going back to 1989, according to data from S&P Global Market Intelligence 1. When this was launched in September 2021, it was supported by a grant of up to $47.5 million).

Disease 162

Disease International Research Science 162

The Pharma Data

JANUARY 18, 2021

“There are no approved therapies for epilepsy caused by SLC13A5 that address the underlying cause of this disease,” said RA Session II, President, Founder and CEO of Taysha. “We Taysha’s commitment to developing a potentially life-changing gene therapy for SLC13A5 deficiency is greatly welcomed by our patient community.”.

Therapies 52

Therapies Disease Treatment FDA 52

Drug Discovery World

JANUARY 24, 2024

Patients experience severe side effects with current medications leading them to discontinue therapy. Phase I of the clinical program will dose healthy volunteers with single ascending doses of FIB992 before proceeding to a multiple ascending dose study where the drug is administered for a two-week period.

Small Molecule 147

Small Molecule Research Pharma Companies Disease 147

Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. The global ADC market is expected to continue this steep upward trajectory and is anticipated to exceed $16 Billion by 2026. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

The Pharma Data

MARCH 31, 2023

This positive opinion paves the way towards Novartis being able to provide children diagnosed with heart failure due to left ventricular systolic dysfunction in the EU and their families with an effective therapy in an age-appropriate formulation, helping to address what is a major unmet need.”

Hospitals 75

Hospitals Trials Treatment Clinical Trials 75

Drug Discovery World

FEBRUARY 2, 2024

He says: “Then, maybe in 2025/2026, we’re ready to apply vast and dramatic AI models, because then we’ll have it.” Ever since the 2020 Nobel Prize was awarded, it’s just gone bonkers: new start-ups, new cell therapy techniques, new assays… All the best attended sessions at SLAS 2023 were CRISPR-based.

Compliance 130

Compliance Science Pharma Companies Engineering 130

LifeSciVC

APRIL 2, 2024

We are confident that there is room for improvement over existing cystic fibrosis (CF) therapies because we have not yet achieved fully normalized function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. And the experience of those around you, including Board members and internal investors.

Science 67

Science Small Molecule International Clinical Development 67

ACTO

DECEMBER 19, 2023

The payoff of, on average, 15+ years of R&D and $2 billion invested to bring a new therapy to market comes down to what is done in the 180 days following a product launch. There is no margin for error, but there is no blueprint for success.

Science 52

Science Marketing Production Therapies 52

The Pharma Data

MAY 2, 2023

Starting in 2026, this facility will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for use in clinical trial phases. This step is crucial for Boehringer Ingelheim to rapidly advance new drug candidates from the company’s vast research pipeline to clinical trials and ultimately to market approval.

Small Molecule 40

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 40

Agency IQ

MAY 17, 2024

At that time, the FDA would no longer be able to award new vouchers to companies, unless the product already had rare pediatric disease designation, and obtained approval before October 1, 2026. Combination products could include standards of care or other therapies owned by the same sponsor as the primary drug.

FDA 40

FDA Disease FDA Approval Production 40

National Institute on Drug Abuse: Nora's Blog

SEPTEMBER 27, 2022

But while treatments such as medications for opioid use disorder (MOUD) or behavioral approaches like cognitive behavioral therapy or contingency management address the biological and behavioral dimensions of an SUD, changes in the brain and behavior take time, as does resolving the radiating impacts of an SUD on an individual’s life.

Research 52

Research Treatment Science Trials 52

The Pharma Data

APRIL 15, 2022

New GSK reaffirms its full-year 2022 guidance, the medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR* at CER**, and long-term sales ambition. billion (£1.5 Myelofibrosis is a fatal cancer of the bone marrow impacting the normal production of blood cells.

FDA Approval 52

FDA Approval Treatment Trials Clinical Trials 52

Agency IQ

FEBRUARY 15, 2024

We have tried to sort guidance documents by topic area.

FDA 40

FDA Science Biosimilars Production 40

The Pharma Data

NOVEMBER 11, 2020

and EU5 by 2026. The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. The DSR therapy is not currently approved for clinical research in the United States or Canada.

Therapies 40

Therapies Marketing Disease Clinical Research 40

National Institute on Drug Abuse: Nora's Blog

NOVEMBER 23, 2022

But even with multiple forms of HIV prevention now available, including pre-exposure prophylaxis (PrEP) pills for people who are HIV-negative and antiretroviral therapy that can help people with HIV maintain an undetectable viral load and thus not transmit the virus, HIV transmission rates remain frustratingly elevated.

Treatment 52

Treatment Virus Research Drugs 52

The Pharma Data

DECEMBER 16, 2020

and EU5 by 2026. The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. The DSR therapy is not currently approved for clinical research in the United States or Canada.

Therapies 40

Therapies Marketing Disease Clinical Research 40

The Pharma Data

JUNE 2, 2022

In July 2021, the US Food and Drug Administration granted Breakthrough Therapy designation for AFX3772 to prevent S. New GSK reaffirms its full-year 2022 guidance and the medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR* at CER**. Phase III is expected to start in the short term.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

MAY 31, 2022

In July 2021, the US Food and Drug Administration granted Breakthrough Therapy designation for AFX3772 to prevent S. New GSK reaffirms its full-year 2022 guidance and the medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR* at CER**. Phase III is expected to start in the short term.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

OCTOBER 14, 2020

Pre-clinical and clinical proof-of-concept data from a first-in-human single dose DSR study demonstrated that single dose DSR therapy was safe and well-tolerated and the positive results were published in the high impact peer-reviewed cardiovascular journal, Circulation. and EU5 by 2026.

Clinical Trials 40

Clinical Trials Clinical Research Therapies FDA 40

The Pharma Data

JANUARY 6, 2021

“We are leveraging our strengths in process development and manufacturing for a wide range of biopharmaceuticals such as antibodies, recombinant proteins, gene therapies and vaccines,” said Martin Meeson , chief executive officer at FUJIFILM Diosynth Biotechnologies.

Packaging 52

Packaging Small Molecule Production FDA Approval 52

The Pharma Data

NOVEMBER 18, 2020

The company continues to believe that, if positive, these trial data could represent a significant value inflection point for the company and its shareholders, confirming Betalutin® as a highly promising new targeted therapy that can address the unmet needs of R/R FL patients. Presentation and live webcast – Q3 2020 results.

Trials 40

Trials Clinical Supply Production Therapies 40

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Based on the acceptable safety profile and the favorable immune response data, including the 4th dose response data, Pfizer received Breakthrough Therapy Designation.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

Agency IQ

JUNE 9, 2023

High-priced cell and gene therapies are being increasingly developed for rare diseases. For example, a comparison of some gene therapy reimbursement shows that the single-treatment CAR-T cell therapy Kymriah (tisagenlecleucel) is reimbursed at 320,000 euros (based on outcome) in Italy, Germany, Spain and France.

Marketing 40

Marketing Biosimilars Regulations Drugs 40

The Pharma Data

NOVEMBER 11, 2020

Strategic alliance with Novo Nordisk to develop novel therapies for kidney diseases. Renewal of contract with CEO Dr Werner Lanthaler for five years until 05 March 2026 (after period-end). Renewal of contract with CEO Dr Werner Lanthaler for five years until 05 March 2026 (after period-end).

Disease 40

Disease Production Drugs Pharmaceuticals 40

The Pharma Data

DECEMBER 12, 2020

It plays a crucial role in many inflammatory and autoimmune diseases across multiple therapy areas, including haematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Rare diseases is a high-growth therapy area with rapid innovation and significant unmet medical need. AstraZeneca PLC. _.

Regulations 75

Regulations International Disease Small Molecule 75